Kornimate/medical-research-clean huggingface dataset:
efficacy of laser hair removal therapy in hs

Conditions: Hidradenitis Suppurativa, Acne Inversa

Summary: hidradenitis suppurativa (hs) is a chronic, recurrent and debilitating inflammatory skin disorder, characterized by painful inflamed nodules, abscesses and tunnels in the skin folds such as the axilla, inguinal region and gluteal area. the primary event in hs is occlusion of the hair follicle. hs is a notoriously difficult to treat disease, because treatment options are limited and evidence based treatments are scarce. prevention of diseases is an important topic in medicine. however, current clinical trials in hs are focusing on anti-inflammatory drugs in patients with severe hs, whereas prevention and treatment of patients with more common mild hs is neglected. laser hair removal therapy is a non-invasive procedure with minimal treatment discomfort for patients. previous limited studies have suggested positive results in favor of laser hair removal therapy in hs. we therefore hypothesize that hair depilation using laser hair removal therapy may prevent the formation of new lesions and flares of the disease. the objective is to assess the efficacy of laser hair removal therapy in patients with mild to moderate hs.


Eligibility criteria:
inclusion criteria: * ihs4 mild to moderate, without tunnels in the axillae. * hs activity in at least one axilla. * age 18 years and over. exclusion criteria: * if the patient is not able or willing to provide informed consent. * if the patient is allergic to clindamycin lotion. * if the patient uses systemic therapy for hs such as antibiotics or biologicals. * if a patient is pregnant.

Keywords: laser hair removal therapy
study to compare verbal scores of children diagnosed with asd who received hyperbaric treatment to those who did not

Conditions: Autism Spectrum Disorder

Summary: a child's ability to effectively communicate with peers, parents, and caregivers impacts their level of independence and quality of personal relationships. this retrospective study will compare the speech development of participants aged 2 - 17 years that received 40 sessions of hbot at 2.0 ata to those who had not. both groups will have a verbal assessment every six months. there were 32 subjects in the hbo group and 33 subjects in the non-hbo group. the statistical analysis will focus on whether hyperbaric oxygen therapy made a significant difference in verbal behavior milestones assessment and placement program (vb-mapp) or assessment of basic language and learning skills (ablls) results.

methods: this was a study designed to retrospectively determine any association between hyperbaric oxygen therapy (hbot) and change in verbal scores in children with autism spectrum disorder (asd). all children aged 2 to 17 years, diagnosed with asd who completed a verbal test every six months (either verbal behavior milestones assessment and placement program or the assessment of basic language and learning skills), received applied behavioral analysis at oxford recovery center (orc) were screened for inclusion, some of whom had elected to receive hbot (at least 40 sessions for 60 minutes at 2.0 ata).

Eligibility criteria:
inclusion criteria: * diagnosed with autism spectrum disorder by a qualified practitioner * obtained medical clearance for hyperbaric oxygen therapy * received applied behavioral analysis at oxford recovery center * received two of the same age appropriate verbal test 6 months apart exclusion criteria: * history of seizure disorder * diagnosis of genetic or mitochondrial mutation

Keywords: hyperbaric oxygen therapy
patient preference, sleep quality, and anxiety/depression: a randomized comparison of etravirine and efavirenz

Conditions: Sleep Disorders

Summary: efavirenz causes neuropsychiatric side effects and sleep disturbance, including vivid dreams, dizziness, and abnormal tiredness. these symptoms are frequent during the first weeks of treatment, with subsequent attenuation but may not completely resolve even years after efavirenz initiation. the investigators plan a twelve week, randomized, placebo-controlled, double-blind study. in group 1, efavirenz will be replaced with efavirenz placebo plus etravirine, in group 2, efavirenz would be continued, and etravirine placebo given in addition. after six weeks, patients in group 1 would switch to the regimen of group 2, and vice versa. the primary endpoint of the trial will be patient preference. sleep quality, daytime sleepiness, and anxiety will also be investigated.


Eligibility criteria:
inclusion criteria: * adult patients \> 18 years * signing the study consent form and agree to change art regimen * stable haart including efv since at least 3 months * hiv-rna below 50 copies for at least 3 months exclusion criteria: * no major psychiatric disease (psychosis, severe depression) diagnosed before the initiation of efv * mentally incompetent patients * pregnancy or lactation women of childbearing potential must use one or two reliable contraceptive methods during the trial, from day 1 to the end of week 12. acceptable methods include the birth control pill, iud, condoms with spermicides. non-acceptable methods include (non-exhaustive list): withdrawal, calendar (onigo method), or spermicides alone. * concomitant renal or hepatic disease: * creatinine above 150 micromol/l * transaminases above 5 times upper normal limit * prothrombin (quick) value below 50%

Keywords: etravirine efavirenz anxiety depression sleep quality hiv nnrti tritherapy compliance stocrin to replace efavirenz in long-term users with etravirine to investigate effect of such replacement on patient preference, sleep quality, daytime sleepiness, and anxiety
value of an intervention to enhance adherence in glaucoma patients

Conditions: Glaucoma

Summary: a one-year, randomized, attention placebo-controlled trial investigating the value of comprehensive adherence specific interventions, over the course of one year, to enhance adherence in both (a) newly diagnosed open-angle glaucoma, or ocular hypertension patients, naive to medical therapy and (b) those who have failed monotherapy with any prostaglandin analogue (and are therefore candidates for adjunctive therapy) who then are randomized to receive only travoprost monotherapy. subjects will be randomized to two different interventions involving direct physician education, each of which will take approximately the same amount of physician time: the first will be intensive adherence education that will continue throughout the year. the second will be intensive eye care education, but without any direct adherence education. all patients participating in the study will be monitored for adherence by the tda. the study will demonstrate for the first time the role of adherence-specific training in improving patient adherence and will validate the tda in monitoring and improving adherence in glaucoma. this will correlate with prior work that has documented that greater adherence is associated with marked improvement in intraocular pressure (iop) control. a second goal will be seeing whether improving adherence will change the course of glaucoma therapy by making therapeutic failures into therapeutic successes by reducing the need for adjunctive therapy using only monotherapy with travoprost.


Eligibility criteria:
inclusion criteria: * newly diagnosed patients with glaucoma * suboptimally controlled patients with glaucoma * untreated baseline iop greater than 21 mm hg but less than 32 mm hg * patients who have not responded satisfactorily to pga therapy * patients who are about to have adjunctive therapy administered * patients who consent to participate in this trial exclusion criteria: * glaucoma patients with high pressure * advanced glaucoma * patients with side effects to pga therapy * unwilling to participate

Keywords: glaucoma adherence teaching
study to evaluate the safety and efficacy of afamelanotide in patients with variegate porphyria (vp)

Conditions: Variegate Porphyria

Summary: the primary objective is to evaluate the impact of afamelanotide on the severity of skin disease in patients with variegate porphyria (vp). the secondary objectives are to evaluate the safety and tolerability of afamelanotide in patients with vp and evaluate the impact of afamelanotide on the quality of life of patients with vp.


Eligibility criteria:
inclusion criteria: * male or female patients with confirmed diagnosis of vp. * patients with vp-related skin symptoms. * aged 18-70 years. exclusion criteria: * allergy to afamelanotide or polymer or to local anaesthetic to be used if applicable. * had two or more acute attacks of hepatic porphyria, as defined by the occurrence or acute porphyric symptoms within 12 months prior to the screening period. * individual history of malignant or premalignant skin lesions. * individual or family history of melanoma. * presence of severe hepatic disease. * renal impairment. * female who is pregnant or lactating. * females of child-bearing potential not using adequate contraceptive or a life-style excluding pregnancy. * sexually active man with a partner of child-bearing potential not using adequate contraceptive measures. * use of any other prior and concomitant therapy which may interfere with the objective of the study, within 30 days prior to the screening period. * participation in a clinical trial within 30 days prior to the screening period.
rt-pa thrombolytic therapy in combination with remote ischemic conditioning for acute ischemic stroke

Conditions: Ischemic Stroke

Summary: the purpose of this study is to determine the safety and feasibility of remote limb ischemic conditioning(ric) in acute ischemic stroke patients who received r-tpa thrombolytic therapy.


Eligibility criteria:
inclusion criteria: * male or female, age≥18; * acute ischemic stroke; * modified rankin scale (mrs) score of 2-5; * mrs score less than 1 before onset of stroke symptom; * onset of stroke symptoms within 4.5h before initiation of intravenous rt-pa thrombolytic therapy; * good compliance for remote ischemic conditioning(ric) therapy; * informed consent obtained. exclusion criteria: * stroke or serious head trauma within the previous 3 months * major surgery or severe trauma with in the preceding 3 months * intracranial hemorrhage * systolic pressure greater than 185 mm hg or diastolic pressure greater than 110 mm hg, or aggressive treatment intravenous medication) necessary to reduce blood pressure to these limits * symptoms rapidly improving * symptoms suggestive of subarachnoid hemorrhage, even if ct scan was normal * gastrointestinal hemorrhage or urinary tract hemorrhage within the previous 21 days * arterial puncture at a noncompressible site within the previous 7 days * seizure at the onset of stroke * platelet count of less than 100,000 per cubic millimeter * received heparin within the 48 hours preceding the onset of stroke and had an elevated partial-thromboplastin time * received oral anticoagulation therapy preceding the onset of stroke and inr greater than 1.7 or prothrombin times greater than 15 seconds * ct showed a multiple infarction (low density area greater than 1/3 cerebral hemisphere) * use or plan to use intervention for diagnosis or treating * intracranial neoplasm, cerebral aneurysm or arteriovenous malformation * severe hepatic or renal dysfunction * contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs. * life expectancy\<1 years * pregnant or breast-feeding women * unwilling to be followed up or poor compliance for treatment * patients being enrolled or having been enrolled
a phase i/ii trial of her-2/neu pulsed dc1 vaccine combined with trastuzumab for patients with dcis

Conditions: Breast Cancer

Summary: the purpose of the study is to treat patients with ductal carcinoma in situ (dcis) with a combined treatment of dc1 vaccine with trastuzumab. in this study the investigators will assess the safety and immunogenicity of the combination therapy. the target population is women over 18 years of age and have a diagnosis of dcis that express her-2 3 positive. participants will receive 6 vaccines along with 2 doses of trastuzumab. this study began at the abramson cancer center of the university of pennsylvania and will continue at h. lee moffitt cancer center and research institute.


Eligibility criteria:
inclusion criteria: * women \>= 18 years. * ductal carcinoma in situ (dcis) that express her-2 3+ on 10% of the dcis that have not had definitive surgery are diagnosed by core biopsy or nl surgical biopsy with positive margins. * patients that are er+ will take anti-estrogen therapy for treatment of their dcis during vaccinations. * women of childbearing age with a negative pregnancy test documented prior to enrollment. * eastern cooperative oncology group (ecog) performance status score of 0 or 1. * women of childbearing potential must agree to use a medically acceptable form of birth control during their participation in the study. * have voluntarily signed a written informed consent in accordance with institutional policies after its contents have been fully explained to them. exclusion criteria * pregnant or lactating. * positive for hiv or hepatitis c at baseline by self-report. * potential participants with coagulopathies, including thrombocytopenia with platelet count \ 1.5 and partial thromboplastin time \> 50 sec * major cardiac illness muga or echo \<50% ef. * pre-existing medical illnesses or medications which might interfere with the study as determined by principal investigator (pi).

Keywords: ductal carcinoma in situ (dcis)
evaluation of outcomes following rotator cuff repair using the regeneten bioinductive implant: a prospective, multi-center global registry

Conditions: Rotator Cuff Injuries

Summary: this prospective, single-arm, multicenter registry is being conducted to collect real world post-market data from patients who are undergoing rotator cuff repair using the regeneten◊ bioinductive implant system. the registry will include up to 50 centers in the united kingdom (uk), europe, australia, and up to 400 patients for the initial evaluation. patients will be treated and evaluated according to standard medical care. outcome data is collected up to 2 years post-surgery.


Eligibility criteria:
inclusion criteria: * subject requires arthroscopic rotator cuff repair (arcr); * patients aged over 18 years old at the time of consent and providing baseline data before undergoing rotator cuff repair surgery (either partial or full thickness tears) will be eligible for this prospective registry. exclusion criteria: * subject who, in the opinion of the investigator, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the registry including mental illness, intellectual disability, and drug or alcohol abuse. * subjects who do not meet the indication or are contraindicated according to specific smith+nephew regeneten system's instructions for use (ifus); * subject that meets the definition of a vulnerable subject per iso14155:2020 section 3.44.

Keywords: rotator cuff repair rotator cuff tear full thickness tear partial thickness tear massive tear regeneten bioinductive implant
a safety study of sgn-cd33a in combination with standard-of-care in patients with aml

Conditions: Acute Myeloid Leukemia; Acute Myelogenous Leukemia

Summary: this study will examine the safety profile of vadastuximab talirine (sgn-cd33a) by itself (monotherapy) or in combination with other standard treatments. the main purpose of this study is to find the best dose and schedule for sgn-cd33a when given in combination with standard induction treatment, in combination with standard consolidation treatment, or by itself for maintenance treatment. this will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of sgn-cd33a. in addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will be assessed.

the study will be conducted in the following distinct parts: part a: induction dose escalation - 7+3 combined with sgn-cd33a (day 1 and day 4 dosing) part b: consolidation dose escalation - consolidation combined with sgn-cd33a; up to 4 cycles of consolidation therapy will be administered after sgn-cd33a (day 1 of each cycle). part c: maintenance - sgn-cd33a monotherapy; up to 24 patients with and up to 24 patient without prior allogeneic stem cell transplant will be treated with sgn-cd33a. both arms will enroll simultaneously. sgn-cd33a will be administered on day 1 of each 6-week cycle for up to 8 cycles. part d: induction plus consolidation - induction/consolidation combined with sgn-cd33a; patients who achieve a cr/cri (with or without a second induction) will receive up to 4 cycles of consolidation therapy administered after sgn-cd33a (day 1 of each cycle). part e: induction dose escalation - 7+3 combined with sgn-cd33a (day 1 dosing)

Eligibility criteria:
inclusion criteria: * all subtypes of acute myeloid leukemia (except for acute promyelocytic leukemia) * eastern cooperative oncology group status of 0 or 1 * adequate baseline renal and hepatic function * central venous access * part specific requirements: eligible to receive induction; achieved cr/cri with standard induction and eligible to receive consolidation; in cr with documented blood count recovery for maintenance exclusion criteria: * previous treatment for mds or mpn for dose escalation cohorts * inadequate lung function * inadequate heart function

Keywords: acute myeloid leukemia antibody-drug conjugate cd33 antigen drug therapy acute myelogenous leukemia
collection of samples usoptival study

Conditions: Colorectal Cancer (CRC); Advanced Adenomas (AA)

Summary: a prospective multi-center observational study. the study will enroll eligible subjects from the united states to optimize the biomarker panel and evaluate the performance of a cfdna marker panel selected by the sponsor for crc and advanced adenoma detection.

this study is designed to prospectively collect blood samples and clinical data from subjects that have a suspected advanced adenoma or have been newly diagnosed with crc scheduled for resection surgery, as well as subjects who are at average-risk of colorectal cancer and who are scheduled for routine colonoscopy examination. subjects interested in participation and who meet inclusion criteria and provide written informed consent will be enrolled in the study. by accepting participation in the study, subjects will consent to provide up to 40 ml of blood at the study visit.

Eligibility criteria:
inclusion criteria: arm a: 1. must be 45-84 years of age. 2. must have a suspected advanced adenoma or be newly diagnosed with crc, still not resected, and scheduled for surgery. 3. able to comprehend, sign, and date the written informed consent document. arm b: 1. must be 45-84 years of age. 2. able and willing to undergo a standard-of-care screening colonoscopy within 60 days. 3. able to comprehend, sign, and date the written informed consent document. exclusion criteria: arm a only: 1. subject with curative biopsy during colonoscopy. arm b only: 1. subjects with positive fit test results in the 6 months preceding enrollment. 2. subject has a current diagnosis of cancer. arms a \& b: 1. subject has a personal history of aerodigestive or digestive tract cancers. 2. subjects having undergone previous partial surgical removal of one or more portions of their colon due to a reason other than colorectal cancer. 3. has a known diagnosis or personal history of any of the following high-risk indications for colorectal cancer: 1. inflammatory bowel disease (ibd) including chronic ulcerative colitis (cuc) and crohn's disease. 2. familial adenomatous polyposis ("fap", including attenuated fap). 3. hereditary non-polyposis colorectal cancer syndrome ("hnpcc" or "lynch syndrome"). 4. serrated polyposis syndrome 5. 2 first-degree relatives (e.g., parents, siblings, and offspring) who have been diagnosed with colon cancer. 6. one first-degree relative with crc diagnosed before the age of 60. 4. a significant disease which, in the investigator's opinion, would exclude the subject from the study. 5. legal incapacity or limited mental capacity. 6. medical or psychological conditions that would not permit the subject to complete the study or sign informed consent. 7. the patient has a known or documented previous or current medical history of infectious diseases that can be transmitted through blood (e.g. hepatitis, hiv, etc.), including patients that have been treated, are currently being treated, or have not been treated for that conditions. 8. the patient is known to be pregnant when recruited or during her participation in the study.
the physiological effect of rcexp on ventilation/perfusion distribution

Conditions: Acute Respiratory Distress Syndrome; Mechanical Ventilation

Summary: with the exception of setting the positive end-expiratory pressure (peep), the expiratory phase is commonly overlooked during mv. the expiratory time constant (rcexp) plays an important role in understanding the mechanical properties of the respiratory system in patients receiving mechanical ventilation. however, it is unclear that the effect of expiratory time constant on the ventilation and perfusion distribution.

with the exception of setting the positive end-expiratory pressure (peep), the expiratory phase is commonly overlooked during mv. the expiratory time constant (rcexp) plays an important role in understanding the mechanical properties of the respiratory system in patients receiving mechanical ventilation. however, it is unclear that the effect of expiratory time constant on the ventilation and perfusion distribution.

Eligibility criteria:
inclusion criteria: adult patients with ards receiving mechanical ventilation no more than 72 hours exclusion criteria: 1. age \<18 years old 2. patient undergoing legal protection 3. contra-indications to eit (e. g. severe chest trauma or wounds) 4. pneumothorax 5. patient undergoing ecmo 6. pregnancy
safety and efficacy of an ophthalmic solution in dry eye disease

Conditions: Dry Eye Disease

Summary: the purpose of this study is to investigate the safety and efficacy of an ophthalmic solution in dry eye disease.


Eligibility criteria:
inclusion criteria: * subjects 18 years of age or older exclusion criteria: * no active ocular conditions of disease
feasibility of virtual reality assistance in prostate biopsy under local anesthesia.

Conditions: Prostate Cancer

Summary: the goal of this clinical trial is to test the impact of virtual reality (vr) assistance for anxiety management of patients undergoing prostate biopsies in local anaesthesia. the main question it aims to answer: - is there a significant decrease on anxiety level thanks to vr-assistance? participants will be equipped with vr headset providing an immersive visual experience accompanied with a hypnoses oriented audio during the entire procedure. researchers will compare standardised anxiety scores with a control group.


Eligibility criteria:
inclusion criteria: * indication for prostate biopsies * informed consent exclusion criteria: * local anaesthesia contra-indication (allergy) * claustrophobia * major cognitive impairment and impossibility of answering the standardised questionnaires

Keywords: virtual reality vr anxiety prostate biopsies transperineal biopsies